Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Cardiology-CTVS
  • Cardiology & CTVS News
  • Sodium Zirconium...

Sodium Zirconium Cyclosilicate Enhances Spironolactone Tolerance in Heart Failure Patients with Hyperkalemia: JACC

Written By : Medha Baranwal |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2024-11-27T09:00:57+05:30  |  Updated On 27 Nov 2024 12:40 PM IST
Sodium Zirconium Cyclosilicate for Hyperkalemia in Patients with Heart Failure
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

USA: The REALIZE-K trial shows that a daily oral potassium binder can safely enable the use of mineralocorticoid receptor antagonists (MRAs) in heart failure patients with reduced ejection fraction (HFrEF) at risk of hyperkalemia.

"After 6 months, 71% of patients taking sodium zirconium cyclosilicate (SZC) maintained normokalemia on spironolactone ≥25 mg daily, compared to 36% on placebo," the researchers reported. The study, presented at the 2024 American Heart Association Scientific Sessions, highlights how hyperkalemia concerns often lead to MRA down-titration or discontinuation in HFrEF patients. The findings were also published online in the Journal of the American College of Cardiology.

Mineralocorticoid receptor antagonists have been shown to improve outcomes in patients with heart failure and reduced ejection fraction (HFrEF), yet they are underutilized in clinical practice. Observational data indicate that hyperkalemia is a major barrier to their optimal use. To address this, Mikhail N. Kosiborod, Saint Luke’s Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, MO, USA, and colleagues assessed the impact of SZC in enhancing the use of spironolactone in patients with HFrEF and hyperkalemia.

For this purpose, the researchers conducted the REALIZE-K (NCT04676646) trial, a prospective, double-blind, randomized-withdrawal study involving participants with HFrEF (NYHA II–IV; left ventricular ejection fraction ≤40%). The participants were receiving optimal guideline-directed therapy, excluding mineralocorticoid receptor antagonists (MRA), and had prevalent or incident MRA-induced hyperkalemia. During the open-label run-in phase, participants underwent spironolactone titration (target: 50 mg/daily), and those with hyperkalemia started sodium zirconium cyclosilicate. Participants with normokalemia (potassium 3.5–5.0 mEq/L) on SZC and spironolactone ≥25 mg/daily were randomized to continue SZC or placebo for 6 months.

The primary endpoint was optimal treatment response, defined as normokalemia on spironolactone ≥25 mg/daily without rescue therapy for hyperkalemia (months 1–6). The trial also included five key secondary endpoints tested hierarchically, and exploratory endpoints focused on a composite of adjudicated cardiovascular death or worsening heart failure events (hospitalizations and urgent visits).

The following were the key findings of the study:

• A total of 203 participants were randomized (102 to SZC, 101 to placebo).

• A higher percentage of SZC-treated participants had an optimal response than placebo-treated participants (71% versus 36%; OR 4.45).

• SZC improved the first four key secondary endpoints compared to placebo:

• Normokalemia on randomization dose of spironolactone without rescue therapy (58% versus 23%; OR 4.58).

• Receiving spironolactone ≥25 mg/daily (81% versus 50%; OR 4.33).

• Time to hyperkalemia (HR 0.51).

• Time to decrease/discontinuation of spironolactone due to hyperkalemia (HR 0.37).

• There was no significant difference in KCCQ-CSS at 6 months between SZC and placebo (-1.01 points).

• Adverse events were similar between SZC and placebo (64% versus 63%), with serious adverse events also balanced (23% vers

• A composite of cardiovascular death or worsening heart failure occurred in 11% of the SZC group (1 CV death, 10 HF events) and 3% of the placebo group (1 CV death, 2 HF events).

The findings showed that in participants with HFrEF and hyperkalemia, SZC significantly increased the proportion of those achieving normokalemia while on the optimal spironolactone dose, and reduced the risk of hyperkalemia and the need for down-titration or discontinuation of spironolactone.

"Although the study was underpowered for clinical outcomes, a higher number of heart failure events were observed in the SZC group compared to placebo, which should be considered in clinical decision-making," the researchers concluded.

Reference:

Kosiborod MN, Cherney DZI, Desai AS, et al. Sodium zirconium cyclosilicate for management of hyperkalemia during spironolactone optimization in patients with heart failure. J Am Coll Cardiol. 2024; Epub ahead of print.

Journal of the American College of Cardiologyheart failure with reduced ejection fraction (HFrEF)sodium zirconium cyclosilicatespironolactone
Source : Journal of the American College of Cardiology
Medha Baranwal
Medha Baranwal

    MSc. Biotechnology

    Dr. Kamal Kant Kohli
    Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story

    Editorial

    National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

    National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

    Relevance of Pioglitazone in Indian T2DM Care Continuum

    Relevance of Pioglitazone in Indian T2DM Care Continuum

    Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

    Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases

    Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases

    View All

    Journal Club Today

    Study Reveals Why Your Immune System Works Better in Daylight

    Study Reveals Why Your Immune System Works Better in Daylight

    View All

    Health News Today

    Health Bulletin 29/May/2025

    Health Bulletin 29/May/2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok